» Articles » PMID: 37572497

Oncometabolite Lactate Enhances Breast Cancer Progression by Orchestrating Histone Lactylation-dependent C-Myc Expression

Overview
Journal Transl Oncol
Specialty Oncology
Date 2023 Aug 12
PMID 37572497
Authors
Affiliations
Soon will be listed here.
Abstract

Due to the enhanced glycolytic rate, cancer cells generate lactate copiously, subsequently promoting the lactylation of histones. While previous studies have explored the impact of histone lactylation in modulating gene expression, the precise role of this epigenetic modification in regulating oncogenes is largely unchartered. In this study, using breast cancer cell lines and their mutants exhibiting lactate-deficient metabolome, we have identified that an enhanced rate of aerobic glycolysis supports c-Myc expression via promoter-level histone lactylation. Interestingly, c-Myc further transcriptionally upregulates serine/arginine splicing factor 10 (SRSF10) to drive alternative splicing of MDM4 and Bcl-x in breast cancer cells. Moreover, our results reveal that restricting the activity of critical glycolytic enzymes affects the c-Myc-SRSF10 axis to subside the proliferation of breast cancer cells. Our findings provide novel insights into the mechanisms by which aerobic glycolysis influences alternative splicing processes that collectively contribute to breast tumorigenesis. Furthermore, we also envisage that chemotherapeutic interventions attenuating glycolytic rate can restrict breast cancer progression by impeding the c-Myc-SRSF10 axis.

Citing Articles

Lactylation: a promising therapeutic target in ischemia-reperfusion injury management.

Wang F, Mu G, Yu Z, Shi Z, Li X, Fan X Cell Death Discov. 2025; 11(1):100.

PMID: 40082399 PMC: 11906755. DOI: 10.1038/s41420-025-02381-4.


Lactylation modification in cancer: mechanisms, functions, and therapeutic strategies.

Lv M, Huang Y, Chen Y, Ding K Exp Hematol Oncol. 2025; 14(1):32.

PMID: 40057816 PMC: 11889934. DOI: 10.1186/s40164-025-00622-x.


Metabolic reprogramming in cancer and senescence.

Zhang Y, Tang J, Jiang C, Yi H, Guang S, Yin G MedComm (2020). 2025; 6(3):e70055.

PMID: 40046406 PMC: 11879902. DOI: 10.1002/mco2.70055.


Cancer-associated fibroblasts promote doxorubicin resistance in triple-negative breast cancer through enhancing ZFP64 histone lactylation to regulate ferroptosis.

Zhang K, Guo L, Li X, Hu Y, Luo N J Transl Med. 2025; 23(1):247.

PMID: 40022222 PMC: 11871786. DOI: 10.1186/s12967-025-06246-3.


Histone lactylation-driven B7-H3 expression promotes tumor immune evasion.

Ma Z, Yang J, Jia W, Li L, Li Y, Hu J Theranostics. 2025; 15(6):2338-2359.

PMID: 39990209 PMC: 11840737. DOI: 10.7150/thno.105947.


References
1.
He Y, Ji Z, Gong Y, Fan L, Xu P, Chen X . Numb/Parkin-directed mitochondrial fitness governs cancer cell fate via metabolic regulation of histone lactylation. Cell Rep. 2023; 42(2):112033. DOI: 10.1016/j.celrep.2023.112033. View

2.
Xiao Y, Jin L, Deng C, Guan Y, Kalogera E, Ray U . Inhibition of PFKFB3 induces cell death and synergistically enhances chemosensitivity in endometrial cancer. Oncogene. 2021; 40(8):1409-1424. PMC: 7906909. DOI: 10.1038/s41388-020-01621-4. View

3.
Santoni M, Rizzo A, Kucharz J, Mollica V, Rosellini M, Marchetti A . Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis. Cancer Immunol Immunother. 2023; 72(6):1365-1379. PMC: 10992808. DOI: 10.1007/s00262-022-03349-4. View

4.
Sonveaux P, Vegran F, Schroeder T, Wergin M, Verrax J, Rabbani Z . Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest. 2008; 118(12):3930-42. PMC: 2582933. DOI: 10.1172/JCI36843. View

5.
Dang C . MYC on the path to cancer. Cell. 2012; 149(1):22-35. PMC: 3345192. DOI: 10.1016/j.cell.2012.03.003. View